Risk of acute liver injury following the nirmatrelvir/ritonavir use

CKH Wong, LY Mak, ICH Au, WY Cheng… - Liver …, 2023 - Wiley Online Library
Background Elevations in alanine aminotransferase (ALT) and aspartate aminotransferase
(AST) were reported as adverse events of nirmatrelvir/ritonavir users in the EPIC‐HR trial …
被引用次数：2 相关文章

Risk of acute liver injury following the nirmatrelvir/ritonavir use.

CKH Wong, LY Mak, ICH Au, WY Cheng… - … : Official Journal of the …, 2023 - europepmc.org
Background Elevations in alanine aminotransferase (ALT) and aspartate aminotransferase
(AST) were reported as adverse events of nirmatrelvir/ritonavir users in the EPIC-HR trial …

Risk of acute liver injury following the nirmatrelvir/ritonavir use

CKH Wong, LY Mak, ICH Au… - … : official journal of …, 2023 - pubmed.ncbi.nlm.nih.gov
Background Elevations in alanine aminotransferase (ALT) and aspartate aminotransferase
(AST) were reported as adverse events of nirmatrelvir/ritonavir users in the EPIC-HR trial …

Risk of acute liver injury following the nirmatrelvir/ritonavir use

CKH Wong, LY Mak, ICH Au, WY Cheng, CH So… - 2023 - dro.deakin.edu.au
Background: Elevations in alanine aminotransferase (ALT) and aspartate aminotransferase
(AST) were reported as adverse events of nirmatrelvir/ritonavir users in the EPIC-HR trial …

Risk of acute liver injury following the nirmatrelvir/ritonavir use

CKH Wong, LY Mak, ICH Au, WY Cheng, CH So… - 2023 - dro.deakin.edu.au
Background: Elevations in alanine aminotransferase (ALT) and aspartate aminotransferase
(AST) were reported as adverse events of nirmatrelvir/ritonavir users in the EPIC-HR trial …